Literature DB >> 14678348

Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.

Janet K Coller1, Niels Krebsfaenger, Kathrin Klein, Renzo Wolbold, Andreas Nüssler, Peter Neuhaus, Ulrich M Zanger, Michel Eichelbaum, Thomas E Mürdter.   

Abstract

AIMS: To characterize the interindividual variability and the individual CYP involved in the formation of alpha-hydroxy-, N-desmethyl- and N-didesmethyl-tamoxifen from tamoxifen.
METHODS: Microsomes from 50 human livers were used to characterize the interindividual variability in the alpha-hydroxylation, N-desmethylation and N-didesmethylation of tamoxifen. Selective inhibitors and recombinant enzymes were used to identify the forms of CYP catalysing these reactions.
RESULTS: The rates of formation of alpha-hydroxy-, N-desmethyl- and N-didesmethyl-tamoxifen were highly variable, and correlated with each other (P < 0.0001). The respective ranges were 0.7-11.4, 25.7-411, and below the limit of quantification--4.4 pmol mg(-1) protein min(-1). Formation of all metabolites was observed with expressed recombinant CYP3A4, inhibited by troleandomycin (65, 77 and 35%, respectively, P < 0.05) and associated with CYP3A4 expression (rs = 0.612, rs = 0.585 and rs = 0.430, P < 0.01, respectively).
CONCLUSIONS: Formation of alpha-hydroxy-, N-desmethyl- and N-didesmethyl-tamoxifen in vitro is highly variable and mediated predominantly by CYP3A4.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14678348      PMCID: PMC1884410          DOI: 10.1046/j.1365-2125.2003.01970.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.

Authors:  S S Dehal; D Kupfer
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

2.  Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.

Authors:  N Chauret; A Gauthier; D A Nicoll-Griffith
Journal:  Drug Metab Dispos       Date:  1998-01       Impact factor: 3.922

3.  Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.

Authors:  H K Crewe; S W Ellis; M S Lennard; G T Tucker
Journal:  Biochem Pharmacol       Date:  1997-01-24       Impact factor: 5.858

4.  Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts.

Authors:  S Shibutani; L Dasaradhi; I Terashima; E Banoglu; M W Duffel
Journal:  Cancer Res       Date:  1998-02-15       Impact factor: 12.701

5.  Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

Authors:  D J Newton; R W Wang; A Y Lu
Journal:  Drug Metab Dispos       Date:  1995-01       Impact factor: 3.922

6.  Effect of tamoxifen feeding on metabolic activation of tamoxifen by the liver of the rhesus monkey: does liver accumulation of inhibitory metabolites protect from tamoxifen-dependent genotoxicity and cancer?

Authors:  A Comoglio; A H Gibbs; I N White; T Gant; E A Martin; L L Smith; S R Gamalero; F DeMatteis
Journal:  Carcinogenesis       Date:  1996-08       Impact factor: 4.944

7.  Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.

Authors:  V A Eagling; J F Tjia; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

8.  Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s.

Authors:  J A Styles; A Davies; C K Lim; F De Matteis; L A Stanley; I N White; Z X Yuan; L L Smith
Journal:  Carcinogenesis       Date:  1994-01       Impact factor: 4.944

9.  Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.

Authors:  C Mani; H V Gelboin; S S Park; R Pearce; A Parkinson; D Kupfer
Journal:  Drug Metab Dispos       Date:  1993 Jul-Aug       Impact factor: 3.922

Review 10.  Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

View more
  5 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

Review 2.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 3.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

Review 4.  Evaluation of in vitro assays for assessing the toxicity of cigarette smoke and smokeless tobacco.

Authors:  Michael D Johnson; Jodi Schilz; Mirjana V Djordjevic; Jerry R Rice; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 5.  Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.

Authors:  Deirdre P Cronin-Fenton; Timothy L Lash
Journal:  Expert Rev Clin Pharmacol       Date:  2011-05       Impact factor: 5.045

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.